The findings in our subgroup analysis for patients with different IPI and stages suggest that low SAMHD1 expression may be more beneficial for those DLBCL patients with moderate to high risk (IPI 2–5) and more advanced stage (III–IV) for which about 60% of patients are diagnosed. Here, SAMHD1 is linked to diffuse large B-cell lymphoma.